Data / Drug companies / Aekyung Industrial Co., Ltd.
Aekyung Industrial Co., Ltd.: 64 products in the FDA NDC directory, labeler code 67225
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Aekyung Industrial Co., Ltd. (labeler code 67225) lists 64 products in the FDA National Drug Code Directory, covering 5 finished drugs by generic name. By type: 64 over the counter drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on April 8, 2026.
The request: Watch Aekyung Industrial Co., Ltd. (FDA labeler code 67225): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 67225
- Products in commercial distribution
- 64
- Packages
- 76
- Finished drugs by generic name
- 5
- Prescription products
- 0
- Over the counter products
- 64
- Flagged as original packager
- 63 of 63 products that carry the flag
- Started marketing in the last 12 months
- 22
- Earliest marketing start
- September 7, 2022
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 64 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 64 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Octinoxate, octocrylene, titanium dioxide | 58 | 1 |
| Octocrylene, homosalate, octisalate, avobenzone | 2 | 17 |
| Octinoxate, titanium dioxide, octocrylene | 2 | 1 |
| Zinc oxide | 1 | 595 |
| Zinc oxide, avobenzone, homosalate, octisalate, octocrylene | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Cream | 63 | 98.4% |
| Kit | 1 | 1.6% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Age20s sunscreen duo | 67225-5333 | Kit | Over the counter monograph drugs | April 8, 2026 |
| Age20s signature essence pact intense cover mini 15c | 67225-5330 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 29w | 67225-5329 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 28n | 67225-5328 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 21n | 67225-5324 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 13c | 67225-5322 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 19c | 67225-5320 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 23w | 67225-5319 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 25n | 67225-5317 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 29c | 67225-5316 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 27w | 67225-5315 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 31n | 67225-5314 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 33w | 67225-5313 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 47n | 67225-5312 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 17n | 67225-5311 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 35n | 67225-5310 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 41n | 67225-5309 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 33n | 67225-5307 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 27c | 67225-5305 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 24w | 67225-5304 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover mini 21w | 67225-5302 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s uv mineral priming sunscreen | 67225-5301 | Cream | Over the counter monograph drugs | November 17, 2025 |
| Age20s signature essence pact intense cover 13c | 67225-5221 | Cream | Over the counter monograph drugs | August 13, 2025 |
| Age20s signature essence pact intense cover 19c | 67225-5220 | Cream | Over the counter monograph drugs | August 13, 2025 |
| Age20s signature essence pact intense cover 23w | 67225-5219 | Cream | Over the counter monograph drugs | August 13, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.